AEMD
$0.28
Aethlon Medical
($.01)
(3.45%)
AEMD
Earnings Whisper ®
N/A
2nd Quarter September 2019
Consensus:  ($0.07)
Revenue:  $0.22 Mil
Wednesday
Nov 13
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AEMD reports earnings?
Beat
Meet
Miss

Where is AEMD's stock price going from here?
Up
Flat
Down
Stock chart of AEMD
Analysts
Summary of analysts' recommendations for AEMD
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Peers
MedtronicVarian Medical SystemsCONMED